Replies to post #320646 on Avid Bioservices Inc (CDMO)

[Protector]

biopharm, yes that is so AND they have THIS problem:

But solid tumors are trickier—they’re made up of a mix of cells with different genetic profiles. Scientists have to figure out which tumor cells matter to the growth of the cancer and which ones don’t. Then they have to design T cells with antigens that can target just those ones and nothing else. An ideal signature would involve two to three antigens that your assassin T cells can use to pinpoint the target with a bullet instead of a grenade.

What substance do we know again that can block the immune system from being suppressed and stimulate the immune system at the same time and activate immune response ? Was that PtdSer?

And letting the body re-produce T-cells that have been engineered in the lab to have a synthetic receptor SPECIALISED for the cancer fight job at hand would be something that is accelerated with an ACTIVE Immune System, wouldn't it? And if you could do that without OX40 (or other toxic alternative that will kill the patient through side-effects even faster then the cancer could) then you would, as proven by the non-solid cancer CAR-T treatments move towards a CURE.

I think the 3 at the bottom of the list can make an attempt. But after north's report on his meeting with Dr. Wolchok, I think we are PAST making attempts. We are finalising and the Q/CC in combination with Dr. Wolchok's statement gives it away.

AIMO

[north40000]

Actually 2....NVS and/or GILD/KITE.

I should have asked[but no time in the rush to exit auditorium]---

"What indication(s) is the clinical trial for?" It could be one of those "seamless" trials for multiple indications that Dr. Gottlieb and Dr. Woodcock have averted to in their RAPS speeches in past months.